Diabetes

Eden Miller, DO, reviews the impact the BGM and diabetes management apps have on the patient, giving clinicians a better ability to personalize treatment and empower the patient.

Experts discuss how the amount of time a patient spends engaging with the BGM and diabetes apps will contribute to managing their diabetes.

Prescriptions for continuous glucose monitoring for patients with T2D are increasing, a new study finds, and the authors report on characteristics of new CGM users.

Reduced risk for 10 different cancers was reported among patients with diabetes treated with SGLT2 inhibitors compared with those not treated.

Your daily dose of clinical news you may have missed.

Results also showed that prediabetes is associated with dementia risk but this risk was explained by the subsequent development of diabetes.

Your daily dose of clinical news you may have missed.

The Endocrine Society's first update on management of hypoglycemia since 2009 emphasizes the value of new technology and therapeutics in minimizing risk.

In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.

Eden Miller, DO, highlights patient engagement with OneTouch Verio Flex meter and the OneTouch Reveal apps and how the data help to manage diabetes.

Elizabeth Holt, MD, FACE and Eden Miller, DO, review glycemic data over a 90-day and 180-day period in patients with diabetes.

Compounded versions of semaglutide, often sold online, may contain salt versions of the molecule and are not evaluated by the FDA for safety or efficacy.

After an acute myocardial infarction, adults with diabetes were over 50% more likely to die after 1 year than those without diabetes, a new study shows.

Your daily dose of clinical news you may have missed.

As indicated by levels of 2 common biomarkers of cardiac injury, 33.4% of US adults with T2D showed evidence of undetected CVD vs only 16.1% of those without T2D.

Your daily dose of clinical news you may have missed.

The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.

New study found that patients living in urban areas were more likely to meet all aspects of key metrics of diabetes care.

Experts provide an overview of a study on the use of the OneTouch Verio Flex meter paired with the OneTouch Reveal mobile application in the management of diabetes.

Elizabeth Holt, MD, FACE and Eden Miller, DO, comment on saving time for the provider and giving patients ownership of their data as benefits of using digital BGM apps in the management of diabetes.

Your daily dose of clinical news you may have missed.

Eden Miller, DO, highlights a lack of knowledge in both the patient and the prescriber as a barrier to effective use of BGM technology in diabetes, as well as the need for personalized care for patients.

Elizabeth Holt, MD, FACE, provides an overview of a study on patients with diabetes using the OneTouch Verio Flex meter, a blood glucose meter (BGM) and OneTouch Reveal, a diabetes-management digital app, in tandem.

The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.

AACE 2023. Deaths among persons with diabetes in the US related to vascular complications increased from 2001 to 2020, primarily driven by renal complications.

Drs Aide Vega and Fernando Carnavali highlight the increased control in both diabetes and kidney function with the use of KidneyIntelX in patients with DKD.

Aida Vega, MD, and Fernando Carnavali, MD, discuss the KidneyIntelX study and the rates of referrals of high-risk DKD patients to specialist care.

Aida Vega, MD, and Fernando Carnavali, MD, review the population characteristics of a study involving the use of KidneyIntelX in DKD.

Your daily dose of clinical news you may have missed.

The 2023 algorithm emphasizes a complication-centric approach, beyond glucose levels, for determining first-line pharmacotherapy.